title: Long noncoding RNA SPRY4-IT1 predicts poor patient prognosis and promotes tumorigenesis in gastric cancer.
abstract: Gastric cancer (GC) is the second common cause of cancer-related death worldwide. Long noncoding RNAs (lncRNAs) are emerging as novel regulators in the cancer paradigm. However, investigation of lncRNAs on GC is still in its infancy. In this study, we focused on lncRNA SPRY4 intronic transcript 1 (SPRY4-IT1) and investigated its expression pattern, clinical significance, biological function, and molecular mechanism in GC. SPRY4-IT1 expression was examined, and its correlation with clinicopathological characteristics and patient prognosis was analyzed. A series of assays were performed to understand the role of SPRY4-IT1 in GC. SPRY4-IT1 expression was elevated in GC tissues and cell lines, and SPRY4-IT1 levels were highly positively correlated with tumor size, invasion depth, distant metastasis, TNM stage, and reduced overall survival (OS) and disease-free survival (DFS). A multivariate analysis showed that SPRY4-IT1 expression is an independent prognostic factor of OS and DFS in patients with GC. Additionally, the results of in vitro assays showed that the suppression of SPRY4-IT1 expression in GC cell line MKN-45 significantly reduced cell proliferation, colony formation, and cell migration/invasion. Moreover, the tumorigenic effects of SPRY4-IT1 were partially mediated by the regulation of certain cyclins and matrix metalloproteinases (MMPs)-related genes. Our data suggest that SPRY4-IT1 plays a critical role in GC tumorigenesis and may represent a novel prognostic marker and potential therapeutic target in patients with GC.
authors.affiliation: Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing Medical University, No. 42 Baiziting Road, Nanjing, 210009, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Peng
authors.affiliation: Laboratory of Cancer Research, Southeast University Affiliated Zhongda Hospital, No. 87 Dingjiaqiao Road, Nanjing, 210012, China.
authors.forename: Guoqiu
authors.initials: G
authors.lastname: Wu
authors.affiliation: Department of Medical Oncology, First People's Hospital of Yunnan Province, No. 175 Jinbi Road, Kunming, 650032, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Fan
authors.affiliation: Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing Medical University, No. 42 Baiziting Road, Nanjing, 210009, China.
authors.forename: Jianzhong
authors.initials: J
authors.lastname: Wu
authors.affiliation: Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing Medical University, No. 42 Baiziting Road, Nanjing, 210009, China. willgeek01@163.com.
authors.forename: Jifeng
authors.initials: J
authors.lastname: Feng
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics*; D063646:Carcinogenesis / Q000235:genetics*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000235:genetics; D011379:Prognosis; D062085:RNA, Long Noncoding / Q000235:genetics*; D013274:Stomach Neoplasms / Q000235:genetics* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D062085:RNA, Long Noncoding
keywords: Biomarker; Gastric cancer; Prognosis; SPRY4-IT1; Tumorigenesis
references.citation: Curr Opin Cell Biol. 2003 Apr;15(2):158-63
references.pmid: 12648671
references.citation: Gastroenterology. 2007 Jan;132(1):330-42
references.pmid: 17241883
references.citation: Med Oncol. 2014 Dec;31(12):346
references.pmid: 25412939
references.citation: Cancer Res. 2011 Jun 1;71(11):3852-62
references.pmid: 21558391
references.citation: Genes Dev. 2009 Jul 1;23(13):1494-504
references.pmid: 19571179
references.citation: Lancet. 2009 Aug 8;374(9688):477-90
references.pmid: 19625077
references.citation: Nat Rev Cancer. 2002 Sep;2(9):657-72
references.pmid: 12209155
references.citation: PLoS One. 2013 Nov 06;8(11):e79598
references.pmid: 24223182
references.citation: Cancer Res. 2011 Oct 15;71(20):6320-6
references.pmid: 21862635
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Tumour Biol. 2014 Aug;35(8):7743-54
references.pmid: 24810925
references.citation: Biochem Biophys Res Commun. 2014 Feb 28;445(1):175-9
references.pmid: 24495805
references.citation: Crit Rev Oncol Hematol. 2004 May;50(2):87-100
references.pmid: 15157658
references.citation: Cell Death Dis. 2014 Jun 26;5:e1298
references.pmid: 24967960
references.citation: Cancer Res. 2013 Feb 1;73(3):1180-9
references.pmid: 23243023
references.citation: JAMA. 2010 May 5;303(17):1729-37
references.pmid: 20442389
references.citation: Cancer Biol Ther. 2002 May-Jun;1(3):226-31
references.pmid: 12432268
references.citation: Cell. 2009 Feb 20;136(4):629-41
references.pmid: 19239885
references.citation: Cancer Res. 2011 Jan 1;71(1):3-7
references.pmid: 21199792
references.citation: Trends Cell Biol. 2011 Jun;21(6):354-61
references.pmid: 21550244
references.citation: Lancet. 2003 Jul 26;362(9380):305-15
references.pmid: 12892963
references.citation: BMB Rep. 2012 Nov;45(11):604-11
references.pmid: 23186998
references.citation: Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):302-8
references.pmid: 20496539